Henan Lingrui Pharmaceutical Co Ltd (600285.SS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE000001501

Price
19.87 CNY
Market cap
11.27 bn CNY
P/E (2025)
14.84
P/S (2025)
2.92
Dividend yield
5.54 %
Net margin
19.71 %
Return on equity (ROE)
22.33 %
Return on assets (ROA)
13.48 %

Henan Lingrui Pharmaceutical Co Ltd financials

Fiscal year20242025
Revenue3.50 bn CNY3.85 bn CNY
Gross profit2.65 bn CNY3.08 bn CNY
Operating income810.30 m CNY838.46 m CNY
EBIT723.74 m CNY883.37 m CNY
Net income722.55 m CNY759.50 m CNY
Diluted EPS – continuing operations1.28 CNY1.34 CNY

Full history since 1997, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Henan Lingrui Pharmaceutical Co Ltd

Henan Lingrui Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China. It operates through Medical and Healthcare Division; and Others segments. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, and tinctures, etc. for various indications, including orthopedic, cardiovascular, cerebrovascular, dermatology, pediatrics, respiratory, nutritional supplements, and anesthesiology. Its products include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, and Shenqi Hypoglycemic capsules. The company also engages in industrial and real estate investment; technology research and development; ecological agriculture; and high-tech activities. Henan Lingrui Pharmaceutical Co., Ltd. was founded in 1992 and is headquartered in Xinyang, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.